NeoTX

NeoTX is a biotechnology company that develops a Selective T-cell Redirection (STR) platform for anticancer immunotherapies. Based in Rehovot, Israel, with an additional office in Princeton, U.S., the company's technology binds a genetically engineered bacterial determinant to the tumor surface, activating immune cells away from the tumor's suppressive environment. This converts a weak immune response into a powerful, safe, and native antibacterial reaction, aiding in the development of effective and safe cancer therapies.